MedTrace Logo

Evaluation of Patients With Methicillin-Resistant Staphylococcus Aureus Hospital-Acquired Pneumonia Treated With Linezolid or Vancomycin

NCT01561469 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 188

Last updated 2014-07-10

Study results available
· View outcomes & findings →

Summary

The objective of this study is to review the local management of patients with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia treated with vancomycin or linezolid with the goal to define if any difference exists among these antimicrobials in regard to clinical and economic outcomes.

Conditions

  • Methicillin-Resistant Staphylococcus Aureus (MRSA)
  • Hospital-Acquired Pneumonia

Interventions

DRUG

Linezolid

Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with linezolid according to routine medical care.

DRUG

Vancomycin

Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with vancomycin according to routine medical care.

Sponsors & Collaborators

  • University of Louisville

    collaborator OTHER

  • Henry Ford Hospital

    collaborator OTHER

  • Summa Health System

    collaborator OTHER

  • Sparrow Health System

    collaborator OTHER

  • Jackson Health System

    collaborator OTHER

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2013-06-30
Completion
2013-06-30

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01561469 on ClinicalTrials.gov